Cervical Dystonia News and Research

RSS

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Researchers develop unique diagnostic tool to detect dystonia from MRI scans

Researchers at Mass Eye and Ear have developed a unique diagnostic tool that can detect dystonia from MRI scans, the first technology of its kind to provide an objective diagnosis of the disorder.

29 Sep 2020

Engineered botox more effective

A new study reports on an engineered botulinum neurotoxin (botox) that is more effective as well as safer to use in various medical procedures. The study was published in March 2020 in the open-access journal PLOS Biology.

17 Mar 2020

New oral splint can reduce tics in children and adults with Tourette syndrome

Tourette syndrome is a neurological disorder characterized by vocal and motor tics, which can contribute to anxiety, depression, and low self-esteem.

10 Sep 2019

Brain activity patterns linked to clinical outcomes achieved through DBS in dystonia patients

Dystonia affects more than 500,000 people across Europe. Globally, it is the third most common movement disorder after Parkinson's disease and essential tremor.

22 Dec 2017

Botulinum neurotoxin type X holds potential to open up new field of toxin therapeutics

Botulinum toxins are currently used on more than 80 medical conditions including Muscle spasms, Overactive bladder, Chronic migraine, Cervical dystonia, Sweating and Cerebral Palsy (CP).

3 Aug 2017

Scientist develops way to detect BoNT in biological samples

Many know Botox as a trendy way to get rid of wrinkles, but the popular drug — made from botulinum neurotoxin (BoNT) — can do more than just fill lines.

23 Sep 2016

Botulinum toxins may cause remote effects by moving between neurons

The botulinum toxins are among the deadliest substances on Earth, and two specific toxins — including the popular drug Botox — have multiple uses for treating many neuromuscular conditions, including frown lines, disabling muscle spasms and migraine headaches.

5 Aug 2016

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache.

27 Apr 2016

AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research.

19 Apr 2016

New treatment may bring hope for people suffering from muscle cramps

A new treatment may bring hope for people who suffer from muscle cramps or spasms from neuromuscular disorders, diseases such as multiple sclerosis or simply from nighttime leg cramps that keep people from sleeping, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.

19 Feb 2015

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

...

26 Sep 2013

Scientists discover how to detect abnormal brain rhythms associated with Parkinson's

A team of scientists and clinicians at UC San Francisco has discovered how to detect abnormal brain rhythms associated with Parkinson's by implanting electrodes within the brains of people with the disease.

5 Mar 2013

Scientists identify gene that causes adult-onset primary cervical dystonia

Researchers have identified a gene that causes adult-onset primary cervical dystonia, an often-painful condition in which patients' necks twist involuntarily.

5 Mar 2012

Merz presents XEOMIN clinical data on dystonia at IDS 2011

New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.

22 Oct 2011

Ipsen first quarter sales increase 6.1% to €285.8 million

Ipsen reported today its sales for the first quarter 2011.

3 May 2011

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.

15 Apr 2011